
    
      Nilotinib is an oral drug. The dose is 400 mg twice daily

      Patients are evaluated every 8 weeks for disease response. Blood work is assessed for safety
      initially weekly, then every 4 weeks. Physical exams are performed initially weekly and then
      decreased to every 4 weeks after the first month.
    
  